Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2017/894. (See end of Document for details)

ANNEX

Annexes III and VII to Regulation (EC) No 999/2001 are amended as follows:

- (1) Annex III is amended as follows:
 - (a) in Chapter A, in Part II, point 8 is replaced by the following:

8. Genotyping

The prion protein genotype for the codons 136, 154 and 171 shall be determined for each positive TSE case in sheep. TSE cases found in sheep of genotypes which encode alanine on both alleles at codon 136, arginine on both alleles at codon 154 and arginine on both alleles at codon 171 shall immediately be reported to the Commission. Where the positive TSE case is an atypical scrapie case the prion protein genotype for the codon 141 shall also be determined.;

- (b) in Chapter B, in Part I(A), point 8 is replaced by the following:
 - 8. The genotype, and, where possible, the breed, of each ovine animal found positive to TSE and sampled in accordance with Chapter A, Part II, point 8.;
- (2) in Annex VII, in Chapter C, in Part 1, the following point 8 is added:
 - 8. Where the Member State allows, in accordance with the second paragraph of point 1, the sampling and genotyping of breeding rams in flocks not participating in the breeding programme, the prion protein genotype for the codons 136, 141, 154 and 171 shall be determined for a minimum sample representative of the entire ovine population of the Member State, either:
 - (a) once every 3 years with a minimum sample of at least 1 560 ovine animals; or
 - (b) at a frequency and with a sample size determined by the Member State based on compliance with the following criteria:
 - (i) the sampling design takes into account relevant epidemiological data collected during previous surveys, including data concerning the prion protein genotype of sheep for the codons 136, 141, 154 and 171 by breed, region, age, sex and flock type;
 - (ii) the sampling design allows at a minimum to detect a change of 5 % in genotype prevalence over a 3-year period, with a 80 % power and 95 % confidence level.

Changes to legislation:

There are currently no known outstanding effects for the Commission Regulation (EU) 2017/894.